Sendhilnathan Ramalingam is an Oncology physician affiliated with Duke University. OpenAlex indexes 41 publications with 1,155 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingIndustry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
4 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
25.7%Thalidomide Analog10.5%Lenalidomide56%Revlimid31%Pomalyst13%Part D≥20 patientsKinase inhibitor10%Brukinsa24%Imatinib Mesylate21%Calquence18%Imbruvica17%Jakafi12%Sprycel8%Part D<11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
18.8%Potassium supplement5%Potassium Chloride81%Klor-Con M2019%Part D<11 patientsCorticosteroid4.3%Prednisone100%Part D≥23 patients+ 4 more classes in this area
Nervous system
16.3%Opioid Agonist5%Oxycodone Hcl66%Methadone Hcl21%Hydromorphone Hcl13%Part D<11 patientsGabapentinoids4.6%Gabapentin100%Part D≥24 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms
Bone Marrow Transplantation
2026 - Food insecurity prior to hematopoietic stem cell transplant is associated with malnutrition and worse outcomes
Bone Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Robert Califf, MD
Duke University
Pamela Douglas, MD
Duke University
Adrian Hernandez, MD
Duke University
John Perfect, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”